Hoffmann Verena

Hoffmann VS, Weiss A, Winkler C, Knopff A, Jolink M, Bonifacio E and Ziegler AG. Landmark models to define the age-adjusted risk of developing stage 1 type 1 diabetes across childhood and adolescence. BMC Med. 2019;17(1):125.
Impact factor 2018: 8.285

Lauseker M, Gerlach R, Worseg W, Haferlach T, Tauscher M, Hasford J and Hoffmann VS. Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based study. Eur J Haematol. 2019;103(4):362-9.
Impact factor 2018: 2.217

Kick K, Assfalg R, Aydin S, Bechtold-Dalla Pozza S, Böcker D, Braig S, Bunk M, Dunstheimer D, Durmashkina A, Ermer U, Gavazzeni A, Gerstl E-M, Heinrich M, Herbst M, Kriesen Y, Kuhnle-Krahl U, Müller H, Nellen-Hellmuth N, Ockert C, Ramminger C, Sindichakis M, Tretter S, Warncke K, Achenbach P, Ziegler A-G, Hoffmann VS. Recruiting young pre-symptomatic children for a clinical trial in type 1 diabetes: Insights from the Fr1da insulin intervention study. Contemporary Clinical Trials Communications. 2018;11:170-3.
Impact factor: 2.658
Beller E, Meinel FG, Schoeppe F, Kunz WG, Thierfelder KM, Hausleiter J, Bamberg F, Schoepf UJ, Hoffmann VS. Predictive value of coronary computed tomography angiography in asymptomatic individuals with diabetes mellitus: Systematic review and meta-analysis. J Cardiovasc Comput Tomogr. 2018;12(4):320-8.
Impact factor: 3.095

Wolf S*, Hoffmann VS*, Habicht A, Kauke T, Bucher J, Schoenberg M, Werner J, Guba M, Andrassy J. Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months. PLoS ONE. 2018;13(4):e0194975.
Impact factor: 2.766

Hoffmann VS, Hasford J, Deininger M, Cortes J, Baccarani M, Hehlmann R. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 2017;143(7):1311-8.
Impact factor: 3.282

Geissler J, Sharf G, Bombaci F, Daban M, De Jong J, Gavin T, Pelouchova J, Dziwinski E, Hasford J, Hoffmann VS. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. Journal of Cancer Research and Clinical Oncology. 2017;143(7):1167-76.
Impact factor: 3.282

Schiergens TS*, Hoffmann V*, Schobel TN, Englert GH, Kreis ME, Thasler WE, Werner J, Kasparek MS. Long-term Quality of Life of Patients With Permanent End Ileostomy: Results of a Nationwide Cross-Sectional Survey. Dis Colon Rectum. 2017;60(1):51-60.
Impact factor: 3.616

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Hoglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017;31(3):593-601.
Impact factor: 10.023

Hoffmann VS*, Neumann L*, Golgert S, von Renteln-Kruse W. Pro-Active Fall-Risk Management is Mandatory to Sustain in Hospital-Fall Prevention in Older Patients--Validation of the LUCAS Fall-Risk Screening in 2,337 Patients. J Nutr Health Aging. 2015;19(10):1012-8.
Impact factor: 2.62

Hoffmann VS*, Baccarani M*, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, Hehlmann R. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336-43.
Impact factor: 12.104

Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, Hellmann A, Prejzner W, Steegmann JL, Mayer J, Indrak K, Colita A, Rosti G, Pfirrmann M. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013;27(10):2016-22.
Impact factor: 9.379

Neumann L*, Hoffmann VS*, Golgert S, Hasford J, Von Renteln-Kruse W. In-hospital fall-risk screening in 4,735 geriatric patients from the LUCAS project. J Nutr Health Aging. 2013;17(3):264-9.
Impact factor: 2.659